{"id":1750,"date":"2011-05-01T12:05:00","date_gmt":"2011-05-01T10:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2011\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring"},"modified":"2022-03-17T14:12:05","modified_gmt":"2022-03-17T13:12:05","slug":"duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2011\/duale-plaettchenhemmung-ist-die-zeit-reif-fuer-ein-therapiemonitoring","title":{"rendered":"Duale Pl\u00e4ttchenhemmung: ist die Zeit reif f\u00fcr ein Therapiemonitoring?"},"content":{"rendered":"<p>Zusammenfassung: Ergebnisse einer monozentrischen Studie (5) zeigen, dass nach Anlage eines koronaren Stents bei 41,7% der Patienten die Aggregation der Thrombozyten mit der Standardtherapie (100 mg\/d ASS plus 75 mg\/d Clopidogrel) unzureichend gehemmt ist. Jeder Dritte hat in einem Thrombozytenfunktionstest eine verminderte Clopidogrel- und jeder F\u00fcnfte eine verminderte ASS-\u201eResponse\u201d. Durch Steigerung der Tagesdosen von ASS [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Ergebnisse einer monozentrischen Studie (5) zeigen, dass nach Anlage eines koronaren Stents bei 41,7% der Patienten die Aggregation der Thrombozyten mit der Standardtherapie (100 mg\/d ASS plus 75 mg\/d Clopidogrel) unzureichend gehemmt ist. Jeder Dritte hat in einem Thrombozytenfunktionstest eine verminderte Clopidogrel- und jeder F\u00fcnfte eine verminderte ASS-\u201eResponse\u201d. Durch Steigerung der Tagesdosen von ASS [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[74,684,495,2686,77,76,3916,73,3917,71,1172,498,65,1033,882,727,72,1031],"class_list":["post-1750","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acetylsalicylsaeure","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-aspirin-resistenz","tag-ass","tag-azetylsalizylsaeure","tag-bocla-plan","tag-clopidogrel","tag-gravitas-studie","tag-herzinfarkt","tag-koronar-stent","tag-koronare-herzkrankheit","tag-myokardinfarkt","tag-prasugrel","tag-stent","tag-thrombozytenaggregationshemmer","tag-ticlopidin","tag-triton-timi-38-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1750"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1750\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}